Results 71 to 80 of about 583,184 (351)

Molecular cancer prevention: Intercepting disease

open access: yesMolecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco   +2 more
wiley   +1 more source

IL-4 and IL-13 Receptor Signaling From 4PS to Insulin Receptor Substrate 2: There and Back Again, a Historical View

open access: yesFrontiers in Immunology, 2018
In this historical perspective, written in honor of Dr. William E. Paul, we describe the initial discovery of one of the dominant substrates for tyrosine phosphorylation stimulated by IL-4.
Achsah D. Keegan   +4 more
doaj   +1 more source

Genome-wide association studies of inflammatory bowel disease in German shepherd dogs [PDF]

open access: yes, 2018
Canine Inflammatory Bowel Disease (IBD) is considered a multifactorial disease caused by complex interactions between the intestinal immune system, intestinal microbiota and environmental factors in genetically susceptible individuals.
Allenspach, Karin   +7 more
core   +6 more sources

Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells

open access: yesFEBS Open Bio, EarlyView.
Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi   +7 more
wiley   +1 more source

Evaluation of the levels of interleukins IL-4, IL-13, IL-5, IL-10 and IL-33 in atopic dermatitis patients with and without dupilumab therapy

open access: yesFrontiers in Immunology
BackgroundInterleukins IL-4, Il-5, IL-10, IL-13 and IL-33 play an important role in atopic dermatitis patients. The aim of our study is to address several knowledge gaps in the understanding of interleukin dynamics in atopic dermatitis patients and the ...
Jarmila Čelakovská   +3 more
doaj   +1 more source

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. [PDF]

open access: yes, 2018
Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may represent a ...
Almeida, Neil D   +4 more
core  

Development of human monoclonal antibodies against TARM1 by yeast display

open access: yesFEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe   +5 more
wiley   +1 more source

Development and characterization of monoclonal antibodies specific for chicken interleukin-13 and their neutralizing effects in chicken primary monocytes

open access: yesPoultry Science, 2020
Compared with mammals, the functionality of chicken cytokines is not well understood because of the unavailability of immune reagents. Mammalian interleukin (IL)-13 is an important Th2 type cytokine with well-known biological functions through its 2 ...
Atul A. Chaudhari   +2 more
doaj   +1 more source

Treatment of uveitis with recombinant human interleukin-13 [PDF]

open access: yesBritish Journal of Ophthalmology, 1998
To evaluate the anti-inflammatory cytokine interleukin-13 (IL-13) for the treatment of uveitis.Uveitis was induced in monkeys by immunisation with human retinal S-antigen. Starting at the onset of disease, the animals were treated with IL-13 at 25 micrograms/kg, or vehicle control, injected subcutaneously once a day for 28 days.
F G, Roberge   +5 more
openaire   +2 more sources

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

open access: yesFEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy